MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Zomedica Corp. Total Assets 2011-2026 | ZOM
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127 M | 207 M | 253 M | 280 M | 280 M | 63 K | 4.18 M | 6.03 M | 5.22 M | 82.1 K | 145 K | 212 K | 97.3 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 280 M | 63 K | 89.5 M |
Quarterly Total Assets Zomedica Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 131 M | 136 M | 143 M | 207 M | 214 M | 220 M | - | 253 M | 275 M | 275 M | 280 M | 280 M | 282 M | 275 M | 278 M | 280 M | 278 M | 280 M | 280 M | 66.1 M | 66.1 M | 66.1 M | 66.1 M | 4.18 M | 4.18 M | 4.18 M | 4.18 M | 6.03 M | 6.03 M | 6.03 M | 6.03 M | 5.22 M | 5.22 M | 5.22 M | 5.22 M | 4.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 282 M | 4.18 M | 134 M |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aurora Cannabis
ACB
|
853 M | $ 3.45 | 0.58 % | $ 86.3 M |  Canada |
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
18.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 1.02 | - | $ 110 M | Canada |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Cronos Group
CRON
|
1.93 B | $ 2.54 | 1.6 % | $ 1.33 B | Canada |
 |
Assertio Holdings
ASRT
|
267 M | $ 11.77 | 1.99 % | $ 836 M | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | - | - | $ 2.06 B |  France |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evolus
EOLS
|
226 M | $ 5.04 | 0.6 % | $ 325 M | USA |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 3.06 | 0.66 % | $ 43 M | USA |
 |
Jupiter Wellness
JUPW
|
7.34 M | - | - | $ 33.6 M | USA |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Harrow Health
HROW
|
399 M | $ 34.91 | 2.38 % | $ 1.28 B | USA |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 8.33 | 3.22 % | $ 426 M | USA |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.42 | 0.71 % | $ 402 M | Canada |
 |
China Pharma Holdings
CPHI
|
14.9 M | $ 0.62 | 2.94 % | $ 10.8 M |  China |
 |
Sundial Growers
SNDL
|
1.35 B | $ 1.44 | -4.64 % | $ 3.37 M | Canada |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 2.58 | -2.27 % | $ 340 M | USA |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 22.69 | -2.45 % | $ 1.05 B | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | USA |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Perrigo Company plc
PRGO
|
8.54 B | $ 9.72 | 4.4 % | $ 1.35 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
223 M | - | - | $ 193 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 2.4 | -2.24 % | $ 2.98 M | USA |
 |
Relmada Therapeutics
RLMD
|
97.6 M | $ 6.18 | 4.57 % | $ 186 M | USA |
 |
Rockwell Medical
RMTI
|
52.2 M | $ 0.96 | 6.61 % | $ 22.4 M | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
59 M | $ 0.9 | 4.68 % | $ 44.9 M | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
TherapeuticsMD
TXMD
|
43.3 M | $ 2.17 | - | $ 22.7 M | USA |
 |
Solid Biosciences
SLDB
|
189 M | $ 7.48 | 2.33 % | $ 305 M | USA |
 |
Veru
VERU
|
60.4 M | $ 2.37 | -0.84 % | $ 320 M | USA |
 |
Tilray
TLRY
|
4.31 B | $ 6.9 | 0.15 % | $ 4.26 B | Canada |
 |
Viatris
VTRS
|
50 B | $ 13.51 | - | $ 16.2 B | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 0.72 | 1.41 % | $ 3.11 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
55.5 M | - | - | $ 55.5 M | USA |